Annovis Bio, Inc. (ANVS)
Score window: Apr. 15, 2025 to Apr. 14, 2026
| Date | Form | Sentiment | Urgency | Summary | Open |
|---|---|---|---|---|---|
| Sep. 30, 2025 | UPLOAD | Neutral/Informational | Low | The SEC has completed its review of Annovis Bio, Inc.'s Form 10-K for the fiscal year ended December 31, 2024. They remind the company and its management of their responsibility f… | Read Filing EDGAR |
| Sep. 29, 2025 | CORRESP | Neutral/Informational | Moderate | Annovis Bio, Inc. has responded to the SEC's request for clarification regarding the breakdown of expenses related to their Alzheimer's and Parkinson's studies as mentioned in the… | Read Filing EDGAR |
| Sep. 19, 2025 | CORRESP | Neutral/Informational | Low | Annovis Bio, Inc. has responded to the SEC's request for additional disclosure in its Form 10-K for the fiscal year ended December 31, 2024. The SEC's letter, dated September 4, 2… | Read Filing EDGAR |
| Sep. 4, 2025 | UPLOAD | Concern from SEC | High | The SEC has issued a comment letter to Annovis Bio, Inc. regarding their Form 10-K for the fiscal year ended December 31, 2024. The SEC is requesting additional information about … | Read Filing EDGAR |